Welcome to our dedicated page for Chemours Co SEC filings (Ticker: CC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Chemours Company filings document formal disclosures for a NYSE-listed global chemistry company with businesses in Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. Recent Form 8-K reports furnish operating results and financial condition updates, including segment commentary on Opteon refrigerants, TiO2 pigment, and other specialty-chemistry markets.
Regulatory filings also cover capital-structure actions, including senior unsecured notes, indentures, guarantees, and redemption of outstanding debt. Definitive proxy materials document board structure, director elections, advisory compensation votes, auditor ratification, equity-incentive plan approval, and other shareholder voting matters.
The Chemours Company adopted an Executive Severance Policy effective October 28, 2025. The policy covers executive officers and designated employees who are involuntarily terminated without Cause or resign for Good Reason. Eligible participants receive accrued and unpaid base salary, bonus or incentive compensation, and vacation pay. The CEO is eligible for a cash severance equal to 2.0 times the sum of base salary, target annual incentive opportunity, and annualized health care subsidy; other executive officers and employees receive 1.0 times that sum. A prorated annual cash incentive is payable based on actual performance for the portion of the year worked.
The policy requires a signed release of claims to receive benefits. It does not supersede any change in control agreements and does not alter the treatment of outstanding equity awards, which remain governed by existing plans and award agreements.
The Chemours Company amended its credit agreement, extending the maturity of its $1,050,000,000 senior secured U.S. dollar term loan (Term Loan B-3) from August 18, 2028 to October 15, 2032. The loan’s pricing was reset to either adjusted Term SOFR + 3.50% or adjusted base rate + 2.50%, at the company’s election.
Separately, several wholly owned European subsidiaries entered a receivables purchase agreement with BNP Paribas Factor allowing sales of eligible receivables up to an aggregate outstanding balance of €180,000,000. The initial term runs through October 14, 2026 with automatic one-year extensions, and Chemours acceded to joint and several liability for seller obligations. Receivables are sold at their nominal amount less customary deductions, with applicable interest and fees payable to BNP.
Chemours director Satterthwaite Livingston received 966 deferred stock units on 09/30/2025, each equal to one share of Chemours common stock and recorded at an acquisition price of $15.84 per unit. After the transaction the reporting person beneficially owns 3,280.0507 shares (direct). The deferred stock units become payable beginning the second calendar year after the reporting person ceases service as a director, so these units represent compensation that vests for payout on termination rather than immediate cash or share delivery. The Form 4 was signed by an attorney-in-fact on 10/02/2025 and identifies the reporting person as a director of Chemours (ticker: CC).
Courtney Mather, a director of Chemours Co (CC), reported acquisition of deferred stock units tied to common shares on 09/30/2025. The Form 4 shows 1,657 deferred stock units were acquired at a reported unit value of $15.84 each. Each deferred stock unit is the economic equivalent of one share of common stock and becomes payable after the director leaves board service. After the reported transaction the filing indicates the reporting person beneficially owns 3,960.9731 shares in a direct ownership form.
Gerardo Familiar Calderon, an officer at The Chemours Company (CC), reported a transaction dated 09/01/2025 in which 1,294 common shares were withheld to satisfy tax obligations on vesting restricted stock units and dividend equivalent units; the withholding was executed at a price of $15.40 per share and no shares were sold. The filing shows 33,949.9429 shares beneficially owned following the transaction; that total was reduced to correct an inadvertent over-reporting in a prior Form 4 filed August 5, 2025. The Form 4 was executed on 09/03/2025 by an attorney-in-fact.
The Chemours Company reported changes to its board leadership. The Board of Directors has appointed Independent Director Mary Cranston as Chair of the Board and Alister Cowan as Lead Independent Director, both effective September 2, 2025. These moves follow the departure of former Chair Dawn Farrell, who has accepted a role with the Canadian government as Chief Executive Officer of the newly created Major Projects Office under the Building Canada Act. The filing confirms this is a governance update and does not discuss changes to the company’s business strategy or financial results.
The Chemours Company reported that Dawn Farrell, Chair of its Board of Directors, has decided to resign from the Board effective September 2, 2025. She is leaving to accept an appointment with the Canadian government as Chief Executive Officer of the newly created Major Projects Office launched by the Prime Minister of Canada under the Building Canada Act.
The Board received her notice on August 29, 2025, and has not yet chosen a successor as Chair. The company states that an announcement about who will become the next Board Chair will be made in the future.
The Chemours Company (CC) reporting person Will David, identified as the company's Chief Accounting Officer, reported a routine tax-withholding transaction tied to vested restricted stock units and dividend equivalent units. On 08/12/2025 2,374 shares were withheld at a price of $12.42 to satisfy tax obligations; no shares were sold and the transaction is exempt under Rule 16b-3. After the withholding, Mr. David beneficially owns 25,189.8011 shares (direct ownership). The filing includes a Power of Attorney as Exhibit 24 and was signed by an attorney-in-fact on 08/14/2025.
Denise Dignam, President & CEO and director of The Chemours Company (CC), purchased common stock on 08/08/2025. The Form 4 shows a purchase of 4,068 shares at a price of $12.06 per share, bringing her total reported beneficial ownership to 191,546.1549 shares. The filing notes the reported total includes directly owned shares, restricted stock units and dividend equivalent units.
The disclosure is a standard Section 16 insider report of a non-derivative acquisition and was submitted via Form 4. No options, conversions or derivative transactions are reported on this filing.
The Chemours Company reported an insider transaction by Shane Hostetter, its Chief Financial Officer. The filing shows 3,021 common shares were withheld to satisfy tax obligations on vesting restricted stock units and dividend equivalent units. The report indicates these withholding transactions were exempt under Rule 16b-3 and that no shares were sold in connection with the withholding.
The filing lists a per-share price of $12 for the withheld shares and shows total beneficial ownership following the transaction of 57,115.1539 shares, which the filer states includes directly owned shares, restricted stock units and dividend equivalent units.